AI Article Synopsis

  • * This study used advanced computational methods to screen a library of small molecules, identifying compound C3 as a promising dual inhibitor of both EGFR and HER2 kinases, displaying effective binding and inhibition properties.
  • * Compound C3 demonstrated strong inhibitory effects on cancer cells with minimal potential side effects, suggesting it could be a viable option for gastric cancer treatment, but further testing is necessary.

Article Abstract

Gastric cancers are caused primarily due to the activation and amplification of the EGFR or HER2 kinases resulting in cell proliferation, adhesion, angiogenesis, and metastasis. Conventional therapies are ineffective due to the intra-tumoral heterogeneity and concomitant genetic mutations. Hence, dual inhibition strategies are recommended to increase potency and reduce cytotoxicity. In this study, we have conducted computational high-throughput screening of the ChemBridge library followed by assays and identified novel selective inhibitors that have a dual impediment of EGFR/HER2 kinase activities. Diversity-based High-throughput Virtual Screening (D-HTVS) was used to screen the whole ChemBridge small molecular library against EGFR and HER2. The atomistic molecular dynamic simulation was conducted to understand the dynamics and stability of the protein-ligand complexes. EGFR/HER2 kinase enzymes, KATOIII, and Snu-5 cells were used for validations. The atomistic Molecular Dynamics simulations followed by solvent-based Gibbs binding free energy calculation of top molecules, identified compound C3 (5-(4-oxo-4H-3,1-benzoxazin-2-yl)-2-[3-(4-oxo-4H-3,1-benzoxazin-2-yl) phenyl]-1H-isoindole-1,3(2H)-dione) to have a good affinity for both EGFR and HER2. The predicted compound, C3, was promising with better binding energy, good binding pose, and optimum interactions with the EGFR and HER2 residues. C3 inhibited EGFR and HER2 kinases with IC values of 37.24 and 45.83 nM, respectively. The GI values of C3 to inhibit KATOIII and Snu-5 cells were 84.76 and 48.26 nM, respectively. Based on these findings, we conclude that the identified compound C3 showed a conceivable dual inhibitory activity on EGFR/HER2 kinase, and therefore can be considered as a plausible lead-like molecule for treating gastric cancers with minimal side effects, though testing in higher models with pharmacokinetic approach is required.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10765126PMC
http://dx.doi.org/10.32604/or.2023.043139DOI Listing

Publication Analysis

Top Keywords

egfr her2
20
egfr/her2 kinase
12
5-4-oxo-4h-31-benzoxazin-2-yl-2-[3-4-oxo-4h-31-benzoxazin-2-yl phenyl]-1h-isoindole-132h-dione
8
gastric cancers
8
her2 kinases
8
atomistic molecular
8
katoiii snu-5
8
snu-5 cells
8
identified compound
8
egfr
5

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!